Lutz Herb, Arias Joshua, Zou Yu
Biomanufacturing Sciences Network, EMD Millipore Corporation, 900 Middlesex Turnpike, Billerica, MA, 01821.
Bioprocess R&D, EMD Millipore Corporation, Bedford, MA, 01730.
Biotechnol Prog. 2017 Jan;33(1):113-124. doi: 10.1002/btpr.2334. Epub 2016 Oct 15.
High therapeutic dosage requirements and the desire for ease of administration drive the trend to subcutaneous administration using delivery systems such as subcutaneous pumps and prefilled syringes. Because of dosage volume limits, prefilled syringe administration requires higher concentration liquid formulations, limited to about 30 cP or roughly 100-300 g L for mAb's. Ultrafiltration (UF) processes are routinely used to formulate biological therapeutics. This article considers pressure constraints on the UF process that may limit its ability to achieve high final product concentrations. A system hardware analysis shows that the ultrafiltration cassette pressure drop is the major factor limiting UF systems. Additional system design recommendations are also provided. The design and performance of a new cassette with a lower feed channel flow resistance is described along with 3D modeling of feed channel pressure drop. The implications of variations in cassette flow channel resistance for scaling up and setting specifications are considered. A recommendation for a maximum pressure specification is provided. A review of viscosity data and theory shows that molecular engineering, temperature, and the use of viscosity modifying excipients including pH adjustment can be used to achieve higher concentrations. The combined use of a low pressure drop cassette with excipients further increased final concentrations by 35%. Guidance is provided on system operation to control hydraulics during final concentration. These recommendations should allow one to design and operate systems to routinely achieve the 30 cP target final viscosity capable of delivery using a pre-filled syringe. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:113-124, 2017.
高治疗剂量需求以及对给药便利性的追求推动了使用皮下泵和预填充注射器等给药系统进行皮下给药的趋势。由于剂量体积限制,预填充注射器给药需要更高浓度的液体制剂,对于单克隆抗体,其限制在约30厘泊或大致100 - 300克/升。超滤(UF)工艺通常用于配制生物治疗药物。本文考虑了超滤工艺中的压力限制,这些限制可能会限制其达到高最终产品浓度的能力。系统硬件分析表明,超滤盒的压降是限制超滤系统的主要因素。还提供了其他系统设计建议。描述了一种具有较低进料通道流动阻力的新型滤盒的设计和性能,以及进料通道压降的三维建模。考虑了滤盒流动通道阻力变化对放大和设定规格的影响。提供了最大压力规格的建议。对粘度数据和理论的综述表明,分子工程、温度以及使用包括pH调节在内的粘度调节剂可以用于实现更高的浓度。低压降滤盒与辅料的联合使用进一步将最终浓度提高了35%。提供了关于系统操作的指导,以在最终浓缩过程中控制液压。这些建议应能使人们设计和操作系统,以常规实现能够使用预填充注射器给药的30厘泊目标最终粘度。© 2016美国化学工程师学会生物技术进展,33:113 - 124,2017。